You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
Abstract: Small Cell Lung Cancer (SCLC) is a specific subtype of lung cancer presenting as highly metastatic disease with extremely poor prognosis. Despite responding initially well to chemo- or radiotherapy, SCLC almost invariably relapses and develops resistance to chemotherapy. This is suspected to be related to tumor cell subpopulations with different characteristics resembling stem cells. Epithelial-Mesenchymal Transition (EMT) is known to play a key role in metastatic processes and in developing drug resistance. This is also true for NSCLC, but there is very little information on EMT processes in SCLC so far. SCLC, in contrast to NSCLC cell lines, grow mainly in floating cell clusters ...
None
Abstract: Despite routine use of DNA-hypomethylating agents (HMAs) in AML/MDS therapy, their mechanisms of action are not yet unraveled. Pleiotropic effects of HMAs include global methylome and transcriptome changes. We asked whether in blasts and T-cells from AML patients HMA-induced in vivo demethylation and remethylation occur randomly or non-randomly, and whether gene demethylation is associated with gene induction. Peripheral blood AML blasts from patients receiving decitabine (20 mg/m2 day 1-5) were serially isolated for methylome analyses (days 0, 8 and 15, n = 28) and methylome-plus-transcriptome analyses (days 0 and 8, n = 23), respectively. T-cells were isolated for methylome analy...
Bewährt, topaktuell und grundlegend überarbeitet erscheint bereits die 5. Auflage des Blauen Buches. Das Blaue Buch steht seit Jahren für eine in der Praxis einfach handhabbare Sammlung von Chemotherapie-Protokollen zur Behandlung von Krebspatienten mit soliden und hämatologischen Tumoren. Wie gewohnt sind auf einen Blick Detailinformationen zu Chemotherapie, Begleitmedikation, Notfallsituationen, Nebenwirkungen, Kontrollen, supportiven Therapien sowie Zusatzinformationen für eine sichere Applikation aufgeführt. Die über 400 umfassend ausgearbeiteten und jahrelang in der Praxis etablierten Behandlungsprotokolle, übersichtlich nach Tumorentitäten und Indikationen geordnet, sind auf B...